A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Bezuclastinib (Primary) ; Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms PEAK
- Sponsors Cogent Biosciences
- 04 Jun 2024 Trial design, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 23 May 2024 According to a Cogent Biosciences Media Release, company expects to complete enrollment in 3Q 2024